Background. Recent studies suggest that CD80 (also known as B7.1) is expressed on podocytes in minimalchange disease (MCD) and may have a role in mediating proteinuria. CD80 expression is known to be induced by Toll-like receptor (TLR) ligands in dendritic cells. We therefore evaluated the ability of TLR to induce CD80 in human cultured podocytes. Methods. Conditionally immortalized human podocytes were evaluated for TLR expression. Based on high expression of TLR3, we evaluated the effect of polyinosinicpolycytidylic acid (polyIC), a TLR3 ligand, to induce CD80 expression in vitro.
Introduction
Idiopathic minimal-change disease (MCD) is the most common nephrotic syndrome in children and adolescents. In 1974, Shalhoub [1] proposed that MCD is a T-cell disorder, based primarily on the lack of immune reactants in the glomeruli, the occasional association of the disease with Hodgkin's lymphoma and the exquisite sensitivity to corticosteroids. Nevertheless, over the last 40 years, the specific etiology of MCD has remained elusive.
A potential clue for the etiology of MCD was provided by Reiser et al. [2] when they demonstrated that podocytes can express CD80 in various proteinuric conditions. CD80 is a costimulatory molecule required for T-cell activation and is primarily expressed by antigen-presenting cells (APC) as well as other cell types including podocytes and renal tubular cells.
The role of CD80 in nonimmune cells in the kidney is not well understood. An important observation was made by Reiser et al. [2] who showed that lipopolyssaccharide (LPS), puromycin and some other stimuli could induce CD80 expression in cultured murine podocytes resulting in actin reorganization. In vivo, LPS injection resulted in proteinuria with the expression of CD80 by podocytes. When LPS was administered to the CD80À/À knockout mouse, no increase in urinary protein excretion was observed. Furthermore, LPS could induce proteinuria in severe combined immunodeficient mice which suggests proteinuria associated with CD80 expression on podocytes could occur independently of B cells and T cells [2] . These studies documented that CD80 expression on podocytes could be a mechanism for proteinuria, likely by inducing podocyte shape change.
Recently, our group has reported that CD80 is increased in the urine [3] and in podocytes of MCD patients with nephrotic syndrome [3, 4] . The mechanism for the induction of CD80 in MCD is not known. However, the observation that LPS induces CD80 [2] raised the possibility that activation of Toll-like receptors (TLRs) could be involved since LPS binds TLR4. This is also consistent with the observation that MCD is commonly induced by viral infection.
We therefore hypothesized that other TLR ligands as well may similarly induce CD80 and podocyte phenotype change. Furthermore, since CD80 expression can be induced in podocytes independently of T cells [2] , we determined if corticosteroids might act directly on the podocyte to inhibit CD80 expression in response to TLR ligands.
Methods

Cell culture
Immortalized human podocytes [5] were obtained from Dr Moin Saleem at the University of Bristol and were maintained in RPMI 1640 containing 10% fetal bovine serum (FBS), 1% insulin-transferrin-selenium-A supplement (Invitrogen, Carlsbad, CA), penicillin (100 U/mL) and streptomycin (100 lg/mL). Cells were grown at 33°C in 95% air, 5% CO2 and then converted to differentiated cells by incubating at 37°C for 10 days. Cells were kept in 1% FBS for 24 h and then treated with TLR1 ligand: Pam3CSK4 (0.5 lg/mL), TLR2 ligand: HKLM (108 cells/mL), TLR3 ligand: polyIC (10-500 ng/mL), TLR4 ligand: LPS (20 lg/mL), TLR5 ligand: flagellin (10 lg/mL), TLR6 ligand: FSL1 (1 lg/mL), TLR7/8 ligand: R848 (5 lg/mL) and TLR9 ligand: CPG-DNA (10 lg/mL) (Invivogen, San Diego, CA) for designated hours. For the analysis of signaling pathways, podocytes were incubated with polyIC (500 ng/ mL) with or without additional dexamethasone (10 À7 to 10 À5 M), type 1 interferon (IFN) blocking peptide B18R (0.2 lg/mL) or nuclear factor kappa B (NF-jB) inhibitor pyrrolidine dithiocarbamate (PDTC) (20 lM) . Cells were used between passages 13-25.
CD80 silenced cell lines by short hairpin RNA
Cultured podocytes were transfected using short hairpin RNA (shRNA) and Lipofectamine 2000 (Invitrogen) as described by the manufacturer. Lipid-DNA complexes are prepared as recommended protocols using growth media without serum. The Lipid-DNA complexes in solution were added to attached cells in low serum media without antibiotics and incubated overnight. Normal serum media with antibiotics were added 24 h posttransfection and media with puromycin was added after 48 h. Stable transfectants (clones) were picked using glass cloning cylinders and were subjected to a 10-fold dilution series, replated and a second colony selection performed to provide a clean clone for further analysis. Multiple clones were ultimately generated followed by validation of functional effectiveness of the specific vector.
Western blot analysis
Cell protein lysates were prepared from confluent cell cultures as described previously [6] . For nuclear and cytoplasm extraction, NE-PER Nuclear and cytoplasmic extraction reagents (Thermo Scientific, Rockford, IL) were used according to the instruction. Sample protein content was determined by the BCA protein assay (Thermo Scientific). Fifty micrograms of total protein were loaded per lane for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% wt/vol) analysis and transferred to polyvinyliden difluoride membranes. Membranes were incubated with primary antibodies and visualized by using a horseradish peroxidase (HRP) secondary antibody (Cell Signaling, Danvers, MA) and the HRP Immunstar detection kit (Bio-Rad, Hercules, CA). Chemiluminescence was recorded with an Image Station 440CF, and results were analyzed with the 1D Image Software (Kodak Digital Science). Blots were also analyzed for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), tubulin for cytosolic fraction and laminA/C for nucleus fraction as a loading control.
F-actin and p65 immunofluorescence
Podocytes were grown and differentiated on glass bottom culture dishes (MatTec, Ashland, MA). Cells were kept in 1% reduced serum for 24 h and stimulated with polyIC for designated hours. After stimulation, cells were fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBST) for 10 min and blocked with 5% milk in PBST (blocking buffer) for 1 h. For staining of p65, cells were incubated overnight with a rabbit polyclonal antibody (Cell Signaling), diluted 1:50 in blocking buffer and then incubated with an Alexa-Fluor 488 goat anti rabbit antibody for 2 h. For F-actin staining, cells were incubated after fixation with an Alexa Fluor 488-conjugated phalloidin antibody (Molecular Probes, Carlsbad, CA) for 2 h. Samples were covered with antifading mounting medium with or without 4',6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA). Preparations were imaged with a 403 water-immersion objective by using a laser scanning confocal microscope (model LSM510; Zeiss).
RNA extraction, reverse transcription and quantitative reverse transcription-polymerase chain reaction
Total RNA was extracted using RNeasy (Qiagen, Valencia, CA) and processed with DNaseI (Qiagen). Each 1 lg of total RNA was reverse transcribed using iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer's protocol. Specific primers are shown in Table 1 . Quantitative real-time polymerase chain reaction (PCR) was performed using i-Cycler (Bio-Rad). Each reaction was carried out in 20 ll total volume containing 10 ll of 23 iQ SYBR Green supermix (Bio-Rad), forward and backward primers at 500 nM and 2 ll of complementary DNA (cDNA). Amplification were performed for 1 cycle at 95°C for 3 min and 45 cycles at 95°C for 15 s and designated annealing temperature for 30 s and 72°C for 30 s. The results were normalized by GAPDH expression. As control, we used cDNA from nonstimulated human peripheral blood mononuclear cells (PBMC), also, we prepared cDNA from purchased total adult human kidney RNA (Bio-Rad). Quantitative reverse transcription-PCR for Cathepsin L was performed using an ABI PRISM 7700 Sequence Detector (PE Applied Biosystems, Foster City, CA) and the primers, Cathepsin L (Hs00377632_m1) and GAPDH, (Hs99999905_m1) were obtained from Applied Biosystems.
Statistical analysis
All data are presented as the mean AE S.D. Data graphics and statistical analyses were performed using Instat (version 3.0) and Prism 4 (both from GraphPad, San Diego, CA). Independent replicates for each data point (n) are identified in figure legends. P<0.05 was recognized as statistically significant.
Results
TLR expression in podocytes
Firstly, we determined if TLR1 through 10 messenger RNA (mRNA) transcripts were expressed in adult human kidneys and human podocytes using PBMC as a positive control. The values shown in Table 2 represent the relative expression compared to PBMC (setting the expression in PBMC ¼ 100). All the values were normalized for GAPDH mRNA expression. Human kidney expressed TLR1-10 mRNA, whereas cultured podocytes expressed TLR1-6 and TLR-9 mRNA. The expression of TLR7, 8 and 10 in podocytes was minimal. TLR3 mRNA expression was the most prominently expressed in both the whole kidney and cultured podocytes. This pattern is similar to what we have also observed in isolated murine glomeruli (data not shown).
TLR 3 and 4 ligands induce CD80 expression in podocytes
To assess whether TLR signaling can activate CD80 expression, we stimulated podocytes with the ligands for TLR1 through 9 for 6 h. Among the various ligands studied, the TLR3 ligand polyIC and TLR4 ligand LPS significantly increased CD80 expression compared to 82 M. Shimada et al.
baseline (6.7 AE 0.7 and 4.2 AE 0.9 fold, respectively) (Figure 1) . Stimulation with ligands for TLR1, 2 and 5-9 did not alter CD80 expression significantly.
The effect of polyIC on podocytes
Since polyIC stimulation induced the highest levels of CD80 expression, we continued our studies utilizing polyIC as our stimulant for podocytes. TLR3 mRNA expression was significantly increased in podocytes after 6-h incubation with polyIC (500 ng/mL) ( Figure 2a ) suggesting polyIC act on podocytes via TLR. PolyIC also increased CD80 mRNA both dose dependently ( Figure  2b ) and time dependently with the maximum expression at 6 h ( Figure 2c ). CD80 protein expression in response to polyIC was confirmed by western blotting with densitometry (Figure 2d and e). PolyIC stimulation also resulted in a decrease in synaptopodin expression by quantitative PCR (data not shown) and western blotting (Figure 2d and f), suggesting podocyte injury. Additionally, polyIC increased Cathepsin L mRNA expression in podocytes after 24 h suggesting that polyIC-induced podocyte injury may involve a similar pathway as has been reported for LPS (Figure 2g ) [7] .
CD80 is required for polyIC-induced podocyte injury
To further understand the role of CD80, stable CD80-silenced clones of podocytes were produced using the shRNA technique. Silencing was verified by reduced CD80 mRNA expression (Figure 3a) . PolyIC treatment of CD80-silenced clones blocked the increase in CD80 protein in response to polyIC (Figure 3b ) and attenuated the decrease in synaptopodin (Figure 3c ) compared with the control cells which were processed with a control irrelevant shRNA. 
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The effect of dexamethasone on CD80 expression and podocyte injury
Corticosteroids are commonly used to treat MCD [8] , raising the question of whether corticosteroids might be able to interfere with TLR-stimulated CD80 expression. Incubation of human podocytes with dexamethasone suppressed both basal and polyIC-induced CD80 mRNA expression at 6 h (Figure 4a ). Consistent with these findings, PolyICstimulated CD80 protein expression by western blot was suppressed by dexamethasone in a dose-dependent manner that was confirmed by densitometery (Figures 4b and c) .
Dexamethasone also increased synaptopodin expression in untreated podocytes and prevented the decrease of synaptopodin in response to polyIC (Figures 4b and d) .
PolyIC induced type1 and type2 interferon
Activation of TLR3 is known to induce both type I and type II interferon-dependent signaling in dendritic cells [9] [10] [11] . Consistent with these findings, treatment of differentiated podocytes with polyIC (500 ng/mL) for 6 h resulted in activation of Type1 interferon signaling as shown by increased mRNA expression of the interferon-stimulated Cultured human podocytes were incubated with TLR 1-9 ligands for 6 h. The TLR 3 ligand, polyIC and the TLR 4 ligand LPS significantly increased CD80 mRNA expression (6.7 6 0.7 and 4.2 6 0.9 fold, respectively). Stimulation with TLR1, 2 and 5-9 ligands did not increase CD80 mRNA expression (n ¼ 3, *** P < 0.001 versus control). Fig. 2 . The effect of polyIC on podocytes. TLR3 mRNA expression is induced at 6 h following incubation with PolyIC (500 ng/mL) (a). PolyIC both dose dependently (b) and time dependently (c) increased CD80 mRNA expression in cultured human podocytes. An increase in CD80 protein in response to polyIC occurred in association with a decrease in synaptopodin protein levels by western blotting (d); these changes were confirmed by densitometry (e and f). PolyIC increased Cathepsin L mRNA expression in podocytes at 24 h (g) (n ¼ 3, *P < 0.05, **P < 0.01, ***P < 0.001 versus control).
genes myxovirus resistance 1 (MX1; Figure 5a ) and interferon-induced protein44 (IFl44) (Figure 5b ) [10, 12] . Type 2 IFN activation was also shown by increased expression of chemokine (C-X-C motif) ligand 9 (CXCL9) ( Figure 5c ) and IFN-c (Figure 5d ). However, blockade of type 1 viral interferon with the specific antagonist B18R (0.2 lg/mL) did not prevent the upregulation of CD80 (Figure 5e ). . We also observed a reduction in CD80 protein in response to polyIC stimulation (b) with a concomitant increase in synaptopodin protein (c) compared with the control cells which were processed with irrelevant shRNA (n ¼ 3, *P < 0.05, **P < 0.01 versus control). Fig. 4 . The effect of dexamethasone on CD80 expression and podocyte injury in response to polyIC. Six hours incubation with dexamethasone (10 À5 M) blocks CD80 mRNA expression both in normal podocytes and in podocytes incubated with polyIC (a). Similarly, the induction of CD80 protein and the reduction in synaptopodin protein in response to polyIC is blunted in the presence of increasing concentrations of dexamethasone (b), with densitometry shown in (c) and (d) (n ¼ 3, *P < 0.05, **P < 0.01).
CD80 induction by polyIC was attenuated by NF-jB inhibition
Stimulation of TLR3 is also known to induce NF-jB activation [11] . To evaluate the activation of NF-jB, podocytes were stimulated with polyIC for 1 h and the translocation of the p65 subunit from the cytoplasm to the nucleus was demonstrated by immunofluorescence, documenting the activation of NF-jB (Figure 6a and b) . Similarly, western blotting of cytosolic and nuclear extracts confirmed the translocation of p65 to the nucleus in polyIC-stimulated cells (Figure 6c and d) . Furthermore, the NF-jB inhibitor PDTC significantly reduced the expression of CD80 following polyIC stimulation (Figure 6e ), documenting that CD80 upregulation in podocytes is dependent on NF-jB activation.
PolyIC-induced actin reorganization in podocytes
Untreated differentiated podocytes demonstrate characteristic central stress fibers (Figure 7a ). In contrast, polyIC stimulation for 20 h resulted in reorganization of the actin cytoskeleton with disruption of central stress fibers and increased F-actin at the cortical ring (Figure 7b) . Addition of dexamethasone with polyIC partly inhibited the actin reorganization induced by polyIC (Figure 7c) . Furthermore, CD80 silencing by shRNA largely prevented actin reorganization (Figure7d and f) , whereas this did not Fig. 5 . PolyIC stimulates interferon signaling pathways in podocytes. Differentiated podocytes were treated with polyIC (500 ng/mL) for 6 h. The activation of type 1 IFN was shown by increased mRNA expression of myxovirus resistance 1 (MX1) (a) and interferon-induced protein44 (IFl44) (b) and type2 IFN activation was shown by increased expression of chemokine C-X-C motif ligand 9 (CXCL9) (c) and IFN-c (d). Inhibition of the type I interferon pathway with the antagonist B18R was not able to prevent the CD80 mRNA expression (e) (n ¼ 3, NS, no significant, *P < 0.05, **P < 0.01, ***P < 0.001 versus control).
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occur following transfection with an irrelevant shRNA (Figure 7e ).
Discussion
TLRs are expressed in various cell types, most notably in APC. TLRs sense the molecular patterns of microbial pathogens and play an important role in both the innate and adaptive immune responses [11] . When TLR ligands bind to the TLRs on APC, inflammatory responses are induced in association with increased expression of activated phenotype markers including CD80, CD86 and the major histocompatibility complex [11] . Emerging evidence suggests that TLRs have an important role in various kidney diseases [13] [14] [15] . Recent studies by Reiser et al. [2] suggest that TLR could have a role in inducing proteinuria in the LPS-injected mouse. This observation, coupled with our recent discovery that podocytes express CD80 in MCD [4] , led us to evaluate the role of TLR in activating podocytes in vitro.
We found that TLR1-6 and -9 are expressed in human podocytes and that TLR3 expression was the highest relative to peripheral blood mononuclear cells and was also induced in response to polyIC (the TLR3 ligand). We also found a similar pattern of TLR3 expression in isolated Fig. 6 . Role of NF-jB in PolyIC stimulation of CD80 in podocytes. In control podocytes, p65 is present in the cytoplasm as noted by the light green fluorescence (nuclei stained with 4#,6-diamidino-2-phenylindole and shown in blue in the right column) (a). With polyIC stimulation, p65 translocates to the nucleus (b). Western blot of nuclear (c) and cytosolic fractions (d) similarly show p65 translocate to the nucleus in response to polyIC. Quantitative PCR shows the effect of treating podocytes with the NF-jB inhibitor PDTC 20 lM with and without polyIC (500 ng/mL) for 6 h. PDTC significantly reduced the expression of CD80 both at basal level and in response to polyIC (e) (n ¼ 3, *P < 0.05). murine glomeruli (data not shown), and this pattern is similar to that observed by Banas et al. [14] . Importantly, polyIC both dose-and time-dependently induced CD80 expression in podocytes in association with a decrease in synaptopodin and actin reorganization consistent with podocyte injury. Documentation that CD80 was critical for polyIC-mediated reduction in synaptopodin and actin reorganization was shown by the absence of polyIC effects in podocytes in which CD80 expression was knocked down with shRNA to CD80. Additionally, polyIC increased Cathepsin L mRNA expression in podocytes suggesting that polyIC induce podocyte injury via a mechanism similar to that reported with LPS [7] . New findings included observations that the signaling mechanism by which polyIC acts on podocytes involves both activation of type 1 and type 2 interferon pathways as well as NF-jB signaling. PolyIC could induce the translocation of p65 to the nucleus confirming NF-jB activation. PDTC (an NF-jB inhibitor) could partially ameliorate polyICinduced CD80 expression.
Since NF-jB is a target for corticosteroid effects, we also tested the hypothesis that corticosteroids may act directly on the podocyte in this model system. Dexamethasone decreased both basal-and polyIC-stimulated CD80 expression in podocytes, in association with preservation of synaptopodin and actin organization. These studies suggest that corticosteroids, which are commonly used in MCD [8] , may act in part via direct effects on the podocyte in addition to effects on T cells and is consistent with other studies showing that corticosteroids may have direct effects on this cell type [16] .
In our study, we found a reduction in synaptopodin mRNA and protein in response to CD80 expression. Some authorities have reported that synaptopodin is not decreased in MCD but rather may be increased [17] . However, a study in childhood MCD did find low synaptopodin expression using quantitative immunostaining, with even lower levels present in focal and segmental glomerulosclerosis [18] . Importantly, the decrease in synaptopodin in our in vitro model can be viewed as a marker of podocyte injury in response to CD80 expression and may not have a pathogenic role in CD80-mediated proteinuria.
Our study found TLR3 to be expressed in podocytes. TLR3 expression has been observed in isolated murine glomeruli [14] . However, one report in human kidneys found TLR3 by immunostaining only in mesangial regions [19] . As immunostaining can be insensitive, it does not rule out the possibility of TLR3 being expressed by podocytes. Furthermore, the observation that TLR3 was increased following polyIC would be consistent with its expression being inducible under certain conditions. Importantly, our studies do not implicate TLR3 as the TLR involved in MCD but rather suggest a pathway by which TLR activation on podocytes may induce CD80 expression and phenotypic changes. It is possible that other TLR may be involved in the proteinuria of MCD. For example, Pawar et al. reported that injection of a TLR ligand for TLR2 could induce massive proteinuria in mice with lupus nephritis but not control mice [20] . It is also possible that under some conditions, different TLR may be upregulated and could mediate the increased glomerular permeability to proteins.
While we document that TLR binding can induce CD80, the CD80 expression induced by TLR3 was transient. We have hypothesized that a 'second hit' is required to maintain the expression of CD80 [21] . One possibility is by continued stimulation by the Th2 cytokine IL-13. IL-13 is overexpressed by T cells in MCD [22] . IL-13 overexpression can also induce an MCD-like nephrotic syndrome in rats [23] . Thus, our studies do not negate the potential involvement of T cells in this disorder. Furthermore, there is increasing evidence that T-regulatory cells are defective in MCD [24] , thus allowing continuous T-cell activation and stimulation that could maintain CD80 expression.
In conclusion, we demonstrate that activation of viralassociated TLR in podocytes can induce CD80 expression and podocyte shape change via an NF-jB-dependent pathway. Corticosteroids were able to block the upregulation of CD80. These studies may provide insight into the pathogenesis of MCD and provide new avenues for research.
